Amgen and AstraZeneca Present Real-World Data for Tezspire in Severe Asthma

Amgen and AstraZeneca today presented real-world evidence from multiple registries and healthcare databases showing that Tezspire (tezepelumab-ekko) significantly reduces severe asthma exacerbations in clinical practice. The data showed a 70% reduction in annualized exacerbation rates compared to pre-treatment periods across diverse patient populations.